Mira Pharmaceuticals, Inc. develops novel oral therapies targeting neurologic, inflammatory, and metabolic diseases. The company focuses on reengineering proven biological mechanisms into safer, orally available treatments. Its lead program, Ketamir-2, is advancing toward Phase 2a clinical trials for chemotherapy-induced peripheral neuropathy (CIPN), while other programs, such as MIRA-55 and SKNY-1, are in various stages of development for chronic inflammatory pain and obesity/nicotine addiction, respectively.
